Zepbound Microdosing: 5 Real Options, Since Lilly Doesn't Sell One

Is there a real "Zepbound microdosing" product, or is this actually compounded tirzepatide?

The honest answer is no, at least not from Eli Lilly. Zepbound is a trademarked brand name attached to one specific, FDA-approved finished drug, and it ships on a fixed dose ladder — 2.5mg to start, climbing in steps to a 15mg ceiling. There has never been a Zepbound SKU below 2.5mg, and nothing in Lilly's public pipeline suggests one is coming. If you're picturing a smaller pen or a lower-numbered box on a pharmacy shelf, that product doesn't exist.

What does exist, and what most "Zepbound microdosing" search results are actually pointing at, is compounded tirzepatide — the same active molecule, mixed by a pharmacy rather than manufactured by Lilly, sold under its generic name rather than the brand. That's a real product with a real legal category, but it is not Zepbound, and a provider that blurs the two is worth a second look. We cover that naming distinction, and the full legal footing behind it, in more depth in compounded Zepbound: what's really sold; this page stays focused on the microdosing question specifically.

• Zepbound — Eli Lilly's brand, FDA-approved, dose ladder starts at 2.5mg. No microdose SKU exists.
• Compounded tirzepatide, marketed as a "microdose" — a separate, pharmacy-mixed product sold by telehealth platforms, often well under 1mg weekly. Legal under a narrower pathway than during the 2022–2024 shortage years.
• The closest "official" middle ground — Zepbound's own 2.5mg starting dose, which Lilly's label itself calls a treatment-initiation step rather than a long-term maintenance dose.

Where can you actually get microdose tirzepatide — the real, named options

This market is narrower than it looks from the ad volume. A lot of GLP-1 platforms built a "microdose" brand around semaglutide, not tirzepatide, so searching the tirzepatide version specifically narrows the field fast. Fridays is the clearest exception: it runs a genuinely separate "Microdose Tirzepatide" product, distinct from its standard weight-loss tirzepatide track, positioned for people already stabilized on a GLP-1 who want to hold their progress rather than start a new titration.

Most of the rest of the field doesn't brand a microdose SKU at all. Mochi Health and Curex both price compounded tirzepatide flat across every dose, so a prescriber choosing to keep your dose lower and slower is a titration decision inside the normal program, not a separate product with its own listing. Willow goes further and says so directly on its own site — no microdose plans, no branded GLP-1s, one flat price regardless of dose. For the fuller survey of every named tirzepatide microdose product on the market, including a couple of smaller platforms not tabled here, see tirzepatide microdosing.

What does Zepbound / tirzepatide microdosing actually cost?

Line the five options up and the spread isn't dramatic — everything on this page falls somewhere between about $200 and $400 a month, whether or not the seller actually calls it a microdose. What differs is what you're buying at that price: a genuinely blended maintenance product at Fridays, a flat-fee titration choice at Mochi or Curex, a flat rate with no microdose framing at all at Willow, or the one option with zero compounded-status question mark, Zepbound's own starting dose through LillyDirect.

• LillyDirect, Zepbound 2.5mg starting dose: about $3,588 a year, on-time refills.
• Fridays Microdose Tirzepatide: roughly $2,376 to $2,976 a year, depending on which SKU applies.
• Mochi Health, flat-dose compounded tirzepatide: about $3,336 a year, all-in.
• Curex, flat starter-dose compounded tirzepatide: about $2,388 a year — the lowest here, though the maintenance-dose ladder isn't public.
• Willow, flat-dose compounded tirzepatide: about $4,788 a year, the highest in this set.

None of these figures include labs or a separate consult fee where one applies, and none of them are Zepbound's full retail price, which runs well over $1,000 a month with no program at all. For the complete brand-name price ladder across every insurance and self-pay scenario, see Zepbound cost.

Zepbound's real FDA dose ladder, and where a "microdose" sits on it

Zepbound's titration schedule, printed on its own FDA label, climbs in steps no sooner than every four weeks, starting at 2.5mg and topping out at 15mg. A compounded "microdose," in the way providers use the term, generally means staying under that ladder's very first rung — not just at its early steps.

For the full ladder in units and vial measurements, plus what happens if you miss a dose, see the complete Zepbound dosage chart.

Is compounded tirzepatide microdosing even legal right now?

Narrowly, yes. The FDA declared the tirzepatide shortage resolved in December 2024, which ended the broad exemption that let large 503B outsourcing facilities compound it without a patient-specific prescription. What survives is the 503A individual-patient pathway: a licensed pharmacy can still compound tirzepatide, including at a low, off-ladder dose, for a specific patient when a prescriber documents a genuine clinical reason the FDA-approved product won't meet — not simply because it costs less. On top of that, the FDA proposed in April 2026 to remove tirzepatide, along with semaglutide and liraglutide, from the 503B bulk drug substances list entirely, a step that would close off large-scale bulk compounding for good; the original comment period on that proposal ran through late June 2026, and it's worth checking whether a final rule has posted by the time you're reading this.

Legality here isn't just about the pathway — it's also about the marketing. Eli Lilly sued four telehealth compounders, including Mochi Health and Willow, in April 2025 over how they advertised compounded tirzepatide, arguing the marketing traded on Lilly's brand reputation without being what it claimed. A federal judge allowed Lilly's core claims against Mochi Health to move forward in 2026, and the cases remain active. None of that makes the underlying molecule fake, but it's a useful signal: a provider that's careful about calling its product "compounded tirzepatide," never "Zepbound," is also the kind of provider that tends to get the rest of the details right.

Is there real science behind tirzepatide microdosing, or is this mostly a trend?

Mostly a trend, with one real mechanism underneath it. Tirzepatide activates both the GIP and GLP-1 receptors, a dual action that's part of why it tends to outperform single-receptor drugs like semaglutide on average weight loss in trials. What that dual mechanism hasn't produced is its own body of microdosing evidence — there is no completed clinical trial testing tirzepatide below its 2.5mg starting point, for weight loss, inflammation, or anything else people are microdosing for. The trial that established the drug's effect, SURMOUNT-1, was built around a clear pattern of more drug producing more weight loss up to the approved ceiling, not around staying deliberately below it.

Are the side effects actually gentler at a microdose?

Probably, but that's an extrapolation, not a measured result. In the trials behind Zepbound's approval, nausea, diarrhea, and constipation were consistently worse right after a dose increase and eased over time — a pattern that lines up with expecting a gentler ride at a lower dose, even though nothing below 2.5mg has actually been tested that way. Hair shedding follows a different logic: it tracks the pace of weight loss itself rather than a direct drug effect, so a slower, lower-dose approach that produces less dramatic weight change would plausibly shed less hair, without that specific claim having been studied at a microdose. One thing that doesn't shrink with the dose: tirzepatide's boxed warning about thyroid C-cell tumors, seen in rodent studies, attaches to the molecule itself, not a dose threshold. Our Zepbound side effects guide has the fuller breakdown at approved doses.

Can you use it for maintenance once you've already reached your goal weight?

This is where tirzepatide microdosing looks different from the starting-low pitch most content on the topic assumes. Fridays' own product is explicitly built for this use case — people already stabilized on a GLP-1 who want to hold their progress rather than begin a fresh titration. There's a genuine, separate line of research exploring whether spacing full-strength doses further apart, rather than shrinking the dose itself, can preserve most of a person's results — a related but mechanically different idea from a compounded microdose. Either approach, dose reduction or spaced-out dosing, is a conversation to have with your prescriber rather than a change to make on your own.

Is this the right starting point for you in perimenopause?

If GI sensitivity already runs high for you — and plenty of women find perimenopause turns up the volume on nausea and bloating that never used to be a problem — a gentler entry into tirzepatide has real appeal, and a slower climb genuinely can mean fewer rough early weeks. It also carries a side benefit worth knowing: pacing weight loss more slowly tends to be easier on lean muscle, which matters more once declining estrogen is already working against it. We go deeper on that specific tradeoff in GLP-1s and muscle loss in perimenopause. The honest counterpoint: a microdose trades some certainty of results for that gentler start, and tirzepatide's own trial data shows a real gap between its lower and higher doses. If meaningful weight or metabolic change is the actual goal, a standard climb toward an approved maintenance dose still has the stronger evidence behind it.

How to tell a legitimate low-dose protocol from a DIY red flag

The line that matters isn't the number on the syringe — it's who's managing it. A legitimate low-dose protocol comes from a licensed prescriber, filled through a named 503A pharmacy, at a dose your provider set and can adjust. A DIY red flag looks different, and it's worth knowing exactly what that looks like before you're tempted to save a step.

• "Compounded Zepbound" as a product name, not a footnote explaining the distinction — a real trademark misuse, not just careless copy.
• No named pharmacy — a legitimate program can tell you which licensed 503A pharmacy fills the prescription and whether it's accredited.
• No clinician evaluation before shipping — a hard stop regardless of price; this is a real dosing-error risk, not a technicality.
• Drawing your own reduced dose from a Zepbound pen or vial without specific instructions — Zepbound's devices aren't designed for repeated, self-measured draws.
• Pricing meaningfully below the roughly $199 floor most legitimate 503A programs currently hold — a price that low is a sign you're not looking at a real compounded product.